Snapshot from Apr 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / HanAll Biopharma
Company

HanAll Biopharma

Tracked across 1 events · 8 articles · First seen Apr 02, 2026 · Last active Apr 02, 2026

Sentiment
-30
Attention
4
Events
1
Relationships
1
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 -30
Business
Immunovant's Batoclimab Fails Phase 3 TED
HanAll Biopharma Co., Ltd. is a partner of Immunovant in the development of batoclimab. The failure of the Phase 3 trials will require HanAll Biopharma Co., Ltd. to review future plans for the drug with Immunovant.
Apr 02, 2026 · 8 articles
Relationships (1)
Immunovant partner ↔ HanAll Biopharma Immunovant and HanAll Biopharma Co., Ltd. are partners in the development of bat
NEWSDESK
Track HanAll Biopharma live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.